Allosteric modulators of class B G-protein-coupled receptors

Current Neuropharmacology

Volumn 5, Issue 3, 2007, Pages 168-179

  Hoare, Sam R J ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Allosteric; Class B; Corticotropin releasing factor; G protein coupled receptor; Glucagon like peptide; Nonpeptide; Parathyroid hormone; Secretin

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; ANTALARMIN; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCIUM; CINACALCET; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DMP 904; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR ANTAGONIST; GLUCOSE; LY 168049; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; SALCATONIN; SR 125543A; T 0632;

ALLOSTERISM; BINDING SITE; BONE TURNOVER; CALCIUM HOMEOSTASIS; COMPETITIVE INHIBITION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTHYROIDISM; LIGAND BINDING; MATHEMATICAL ANALYSIS; MIGRAINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; REVIEW;

EID: 45749127879     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015907781695928     Document Type: Review

References (92)

1. Al-Sabab, S., Donnelly, D. (2003) A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br. J. Pharmacol., 140, 339-346.
2. Bale, T.L., Vale, W.W. (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol., 44, 525-557.
3. Bergwitz, C., Gardella, T.J., Flannery, M.R., Potts, J.T., Jr., Kronenberg, H.M., Goldring, S.R., Juppner, H. (1996) Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. Evidence for a common pattern of ligand-roceptor interaction. J. Biol. Chem., 271, 26460-26472.
4. Bisello, A., Adams, A.E., Mierke, D.F., Pellegrini, M., Rosenblatt, M., Suva, L.J., Chorev, M. (1998) Parathyroid hormone-reccptor interactions identified directly by photocross-linking and molecular modeling studies. J. Biol. Chem., 273, 22498-22505.
5. Bringhurst, F.R., Demay, M.B., Kronenberg, H.M. (1998) Hormones and disorders of mineral metabolism. In: Larsen, P.R. Ed, Williams Textbook of Endocrinology. Philadelphia, W.B. Saunders Company. pp. 1155-1210.
6. Cascieri, M.A., Koch, G.E., Her, E., Sadowski, S.J., Louizides, D., de Laszlo, S.E., Hacker, C., Hagmann, W.K., MacCoss, M., Chicchi, G.G., Vicario, P.P. 1999) Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J. Biol. Chem., 274, 8694-8697.
7. Castro, M., Nikolacv, V.O., Palm, D., Lobse, M.J., Vilardaga, J.P. (2005) Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc. Natl. Acad. Sci. USA, 102, 16094-16089.
8. Chen, C., Wilcoxen, K.M., Huang, C.Q., Xie, Y.F., McCarthy, J.R., Webb, T.R., Zhu, Y.F., Saunders, J., Liu, X.J., Chen, T.K., Bozigias, H., Grigoridis, D.E. (2004) Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7- dipropylaminopyrazolol 5-alpyrimidine (NB1 30775/R121919) and structure- activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J. Med. Chem., 47, 4787-4798.
9. Chen, Y.L., Mansbach, R.S., Winter, S.M., Brooks, E., Collins, J., Corman, M.L., Dunaiskis, A.R., Faraci, W.S., Gallaschun, R.J., Schmidt, A., Schulz, D.W. (1997) Synthesis and oral efficacy of a 4-( butylethylamino) pyr-rolo [2,3-dpynmidme: a centrally active coiticotropin-releasing factor1 receptor antagonist. J. Med. Chem., 40, 1749-1754.
10. Christopoulos, A., Parsons, A.M., El-Fakahany, E.E. (1999) Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor. J. Pharmacol. Exp. Ther., 289, 1220-1228.
11. Couvineau, A., Tan, Y.V., Cersudo, E., Lacapere, J.J., Murail, S., Neumann, J.M., Laburthe, M. (2006) The human VPAC1 receptor: identification of the N-terminal ectodoman as a major VIP-binding site by photoaffinity labeling and 3D modeling. Ann N. Y. Acad. Sci., 1070, 205-209.
12. Dautzenberg F. M., Kilpatrick, G.J., Hauger, R.L., Moreau, J. (2006) Molecular biology of the CRH receptor- in the mood. Peptides, 22, 753-760.
13. de Laszlo, S.E., Hacker, C. L., B., Kim, D., MacCoss, M., Mantlo, N., Plvnichny, J.V., colwell, L., Koch, G.E., Cascieri, M.A., Hagmann, W.K. (1999). Potent orally absorbed glucagon receptor antagonist. Bioorg. Med. Chem. Lett., 9, 641-646.
14. Denn, T., Linglart, A., Mahon, M.J., Bastepe, M., Juppner, H., Potts, J.T., Jr., Gardella, T.J. (2006) Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTR-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol. Endocrinol., 20, 931-943.
15. DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D:, Fineman, M.S., Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092-1100.
16. Dong, M., Miller, L.J. (2006) Use of photoaffinity labeling to understand the basis: of tigand binding to the secretin receptor. Ann. N. Y. Acad. Sci., 1070, 248-264.
17. Donnelly, P. (1997) The arrangement of the transmembrane helices in the seeretin receptor family of G-protein-couplcd receptors. FEBS Lett., 409, 431-436.
18. Drucker, D.J. (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care, 26, 2910-2940.
19. Drucker, D.J., Nauck, M.A. (2006) The incretin system: glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368, 1696-1705.
20. Dunn, A.J., Swiergiel, A.H., Palamarchouk, V. (2004) Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann. N. Y. Acad. Sci., 1018, 25-34.
21. Foord, S.M., Jupe, S., Holbrook, J. (2002) Bioinformatics and type II G-protein-coupled receptors. Biochem. Soc. Trans., 30, 473-479.
22. Gardella, T.J., Luck, M.D., Fan, M.H., Lee, C. (1996) Transmembrame residues of the parathyroid hormone (PTH)/PTH-related peptide receptor that specifically affect binding and signaling by agonist ligands. J. Biol. Chem., 271, 12820-12825.
23. Gilligan, P.J., Baldauf, C., Cocuzza, A., Chidester, D., Zaczek, R., Fitzgerald, L.W., McElroy, I., Smith, MA., Shen, H.S., Saye, J.A., Christ, D., Trainor, G., Robertson, D.W., Hartig, P. (2000) The discovery of 4-(3-pentylamino) -2,7-dimethyl-8-(2-mplhyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a coiticotropin-releasing factor (hCRF1) antagonist. Bioorg. Med. Chem., 8, 181-189.
24. Gilligan, P.J., Robertson, D.W., Zaczek, R. (2000) Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem., 43, 1641-1660.
25. Grace, C.R., Perrin, M.H., DiGruccio, M.R., Miller, C.L., Rivier, J.E., Vale, W.W., Riek, R. (2004) NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc. Natl. Acad Sci. USA, 101, 12936-12941.
26. Green, S.A., Spasoff, A.P., Coleman, R.A., Johnson, M., Liggett, S.B. (1996) Sustained activation of a G protein-coupled receptor via "anchored" agonist binding.Molecular localization of the salmeterol exosite within die 2-adrenergic receptor. J. Biol. Chem., 271, 24029-24035.
27. Griebel, G., Simiand, J., Steinberg, R., Jung, M., Gully, D., Roger, P., Geslin, M., Scatton, B., Maffrand, J.P., Soubrie, P. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N- [(1S)-2-cyclopropyl-1 -(3-fluoro-4-methylphenyl)ethyl] 5-mcthyl-N-(2-propynyl)- 1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther., 301, 333-345.
28. Grigoriadis, D.E. (2005) The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin. Ther. Targets, 9, 651-684.
29. Gross, R.S., Guo, Z., Dyck, B., Coon, T., Huang, C.Q., Lowe, R.F., Marinkovic, D., Moorjani, M., Nelson, J., Zarmani-Kord, S., Grigoriadis, D.E., Hoare, S.R., Crowe, P.D., Bu, J.H., Haddach, M., McCarthy, J., Saunders, J., Sullivan, R., Chen, T., Williams, J.P. (2005) Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists. J. Med. Chem., 48, 5180-5793.
30. Harmar, A.J., Arimura, A., Gozes, L., Journot, L., Laburthe, M., Pisegna, J.R., Rawlings, S.R., Robberecht, P., Said, S.I., Sreedharan, S.P., Wank, S.A., Waschek, J.A. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev., 50, 265-270.
31. He, L., Gilligan, P.J., Zaczek, R., Fitzgerald, L.W., McElroy, J., Shen, H.S., Saye, J.A., Kalin, N.H., Shelton, S., Christ, D., Trainor, G., Hartig, P. (2000) 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl) pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable-CRF(1) receptor antagonist. J. Med. Chem., 43, 449-456.
32. Heinrichs, S.C., Koob, G.F. (2004) Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J. Pharmacol. Exp. Ther., 311, 427-440.
33. Hoare, S.R. (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov. Today, 10, 417-427.
34. Hoare, S.R., Brown, B.T., Santos, MA, Malany, S., Betz, S.F., Grigoriadis, D.E. (2006) Single amino acid residue determinants of non-peptide entagonist binding to the corticotropin-releasing factor1 (CRFI1 receptor. Biochem. Pharmacol., 72, 244-255.
35. Hoare, S.R., Gardella. T.J., Usdin, T.B. (2001) Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor. Effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation. J. Biol. Chem., 276, 7741-7753.
36. Hoare, S.R., Sullivan, S.K., Fan, J., Khongsaly, K, Grigoriadis, D.E. (2005) Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides, 26, 457-470.
37. Hoare, S.R., Sullixan, S.K., Ling, N., Crowe, P.D., Grigoriadis, D.E. (2003) Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol. Pharmacol., 63, 751-765.
38. Hoare, S.R., Sullivan, S.K., Schwarz, DA., Ling, N., Vale, W.W., Crowe, P.D., Grigoriadis, D.E. (2004) Ligand affinity for amino-tenninal and jux-tamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry, 43, 3996-4011.
39. Hoare, S.R., Usdin, T.B. (2001) Molecular mechanisms of ligand recognition by parathyroid hormone 1 (PTH1) and PTH2 receptors. Curr. Pharm. Des., 7, 689-713.
40. Holsboer, F. (2001) Stress, hypercortisolism and corticostcroid receptors in depression: implicatons for therapy. J. Affect. Disord., 62, 77-91.
41. Holtmann, M.H., Hadac, E.M., Miller, L.J. (1995) Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J. Biol. Chem., 270, 14394-14398.
42. Jack, D. (1991) The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists. Br. J. Clin. Pharmacol., 31, 501-514.
43. Kehne, J., De Lombaert, S. (2002) Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr. Drug Target CNS Neurol. Disord., 1, 467-493.
44. Knudsen, L.B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J.T., Holst, J.J., Jeppesen, C.B., Johnson, M.D., de Jong, J.C., Jorgensen, A.S., Kercher, T., Kostrowicki, J., Madsen, P., Olesen, P.H., Petersen, J.S., Poulsen, F., Sidelmann, U.G., Sturis, J., Truesdale, L., May, J., Lau, J. (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. USA, 104, 937-942.
45. Kurukulasuriya, R., Link J.T., Madar, D.J., Pei, Z., Richards, S.J., Rohde, J.J., Souers, A.J., Szczepankiewicz, B.G. (2003) Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production. Curr. Med. Chem., 10, 123-153.
46. Laburthe, M., Couvineau, A., Maric, J.C. (2002) VPAC receptors for VIP and PACAP. Recept. Channels, 8, 137-153.
47. Lazareno, S., Birdsail, N.J. (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol., 48, 362-378.
48. Liaw, C.W., Grigoriadis, D.E., Lorang, M.T., De Souza, E.B., Maki, R.A. (1997) Localization of agomst- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol., 11, 2048-2053.
49. Lopez de Maturana, R., Willsbaw, A., Kuntzsch, A., Rudolph, R., Donnelly, D. (2003) The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affitifty than GLP- 1. J. Biol. Chem., 278, 10195-10200.
50. Luck, M.D., Carter, P.H., Gardella, T.J. (1999) The (1-14) fragment of parathyroid hormone (PTH) activates intact and amino-tenninally truncated PTH-1 receptors. Mol. Endocrinol., 13, 670-680.
51. Mannstadt, M., Juppner, H., Gardella, T.J. (1999) Receptors for PTH and PTHrP: their biological importance and functional properties. Am. J. Physiol., 277, F665-675.
52. Mayo, K.E., Miller, L.J., Bataille, D., Dalle, S., Goke, B., Thorens, B., Drucker, D.J. (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev., 55, 167-194.
53. McCarthy, JR., Heinrichs, S.C., Grigoriadis, D.E. (1999) Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor sub-types and clinical indications. Curr. Pharm. Des., 5, 289-315.
54. McDermott, M.T., Kidd, G.S. (1987) The role of calcitonin in the development and treatment of osteoporosis. Endocr. Rev., 9, 377-390.
55. Mesleh, M.F., Shirley, W.A., Heise, C.E., Ling, N., Maki, R.A., Laura, R.P. (2007) NMR structural characterization of a minimal peptide antagonist bound to the extracellular domain of the corticotropin-releasing factor1 (CRF1) receptor. J. Biol. Chem., 282, 6338-6346.
56. Meyer, S.E., Chrousos, G.P., Gold, P.W. (2001) Major depression and the stress system: a life span perspective. Dev. Psychopathol., 13, 565-580.
57. Morfis, M., Christopoulos, A., Sexton, P.M. (2003) RAMPs: 5 years on, where to now? Trends Pharmacol. Sci., 24, 596-601
58. Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A-B., Eriksen, E.F., Ish-Shalom, S., Genant, H.K., Wang, O., Mitlak, B.H. (2001) Effect of parathyroid hormone (1-34) on fracturess and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 344, 1434-1441.
59. Nielsen, S.M., Nielsen, L.Z., Hjorth, S.A., Perrin, M.H., Vale, W.W. (2000) Constitutive-activation of tethered-peptide/ corticotropin-releasing factor receptor chimeras. Proc. Natl. Acad. Sci. USA, 97, 10277-10281.
60. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A. Le Trong, I., Teller, D.C., Okada, T., Stenkamp, R.E., Yamamoto, M., Miyano, M. (2000) Crystal structure of rhodopsin: A G protein-coupled-receptor. Science, 289, 739-745.
61. Perrin, M.H., DiGruccio, M.R., Koerber, S.C., Rivier, J.E., Kunitake, K.S., Bain, D.L., Fischer, W.H., Vale, W.W. (2003) A Soluble Form of the First Extracellular Domain of Mouse Type 2beta Corticotropin-releasing Factor Receptor Reveals Differential Ligand Specificity. J. Biol. Chem., 278, 15595-15600.
62. Perrin, M.H., Grace, C.R., Rick, R., Vale, W.W. (2006) The three-dimensional structure of the N-terminal domain of. corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors. Ann. N. Y. Acad. Sci., 1070, 105-119.
63. Perrin, M.H., Sutton, S., Bain, D.L., Berggren, W.T., Vale, W.W. (1998) The first extracellulair domain of corticotropin releasing factor-R1 contains major binding determinants for urucortin and astressin. Endocrinology, 139, 566-570.
64. Perrin, M.H., Vale, W.W. Corticotropin-releasing factor receptors and their ligand family. Annals New York Academy of Sciences. 1999; pp. 312-328.
65. Pham, V., Dong, M., Wade, J.D., Miller, L.J., Morton, C.J., Ng, H.L., Parker, M.W., Sexton, P.M. (2005) Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling. J. Biol. Chem., 280, 28610-28622.
66. Potts, J.T. (2005) Parathyroid hormone: past and present. J. Endocrinol., 187, 311-325.
67. Poyner, D.R., Sexton, P.M., MarshaIll I., Smith, D.M., Quirion, R,, Bom, W., Muff, R., Fischer, J.A., Foord, S.M. (2002) International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenome-dullin, amylin, and calcitonin receptors. Pharmacol. Rev., 54, 233-246.
68. Rivier, J., Rivier, C., Vale, W. (1984) Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science, 224, 889-891.
69. Rocha e Silva, M. (1969) A thermodynamic approach to problems of drug antagonism I. The "Charniere theory". Eur. J. Pharmacol., 6, 294-302.
70. Rocha e Silva, M., Beraldo, W.T. (1948) Dynamics of recovery and measure of drug antagonism. Inhibition of smooth muscle by lysocithin and antihistaminics. J. Pharmacol. Exp. Ther., 93, 457-469.
71. Rodbell, M., Krans, H.M., Pohl, S.L., Birnbaumer, L. (1971) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. 3. Binding of glucagon: method of assay and specificity. J. Biol. Chem., 246, 1861-1871.
72. Rolz, C., Pellegrini, M., Mierke, D.F. (1999) Molecular characterization of the receptor-ligand complex for parathyroid hormone. Biochemistry, 38, 6397-6405.
73. Rubin, M.R., Bilezikian, J.P. (2003) New anabolic therapies in osteoporosis. Endocrinol. Metab. Clin. North Am., 32, 285-307.
74. Runge, S., Wulff, B.S., Madsen, K., Brauner-Osborne, H., Knudsen, L.B. (2003) Different domains of the glucagon and glucagon-like peptido-1 receptors provide the critical determinants of ligand selectivity. Br. J. Pharmacol., 138, 787-794.
75. Salvatore, C.A., Mallee, J.J., Bell, I.M., Zartman, C.B., Williams, T.M., Koblan, K.S., Kane, S.A. (2006) Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry, 45, 1881 -1887.
76. Sheikh, S.P., Vilardarga, J.P., Baranski, T.J., Lichtarge, O., Iiri, T., Meng, E.C., Nissenson, R.A., Bourne, H.R. (1999) Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between-holices III and VI block activation. J. Biol. Chem., 274, 17033-17041.
77. Sherwood, N.M., Krueckl, S.L., McRory, J.E. (2000) The origin and function of the pituitary adenylate eyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev., 21, 619-670.
78. Shimizu, M., Carter, P.H., Gardella, T.J. (2000) Autoactivation of type-1 parathyroid hormone receptors containing a tethered ligand. J. Biol. Chem., 275, 19456-19460.
79. Shimizu, N., Guo, J., Gardella, T.J. (2001) Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha aminoisabutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 reccptor. J. Biol. Chem., 276, 49003-49012.
80. Sloop, K.W., Michael, M.D., Moyers, J.S. (2005) Glucagon as a target for the treatment of Type 2 diabetes. Expert Opin. Ther. Targets, 9, 593-600.
81. Smagin, G.N., Heinrichs, S.C., Dunn, A.J. (2001). The role of CRH in behavioral responses to stress. Peptides, 22, 713-724.
82. Steddon, S.J., Cunningham, J. (2005) Calcimimetics and calcilytics-fooling the calcium receptor. Lancet, 365, 2237-2239.
83. Stewart, J.M., Freer, R.J., Rezende, L., Pena, C., Matsueda, G.R. (1976) A pharmacological study of the angiotensin receptor and tachyphylaxis in smooth muscle. Gen. Pharmacol., 7, 177-183.
84. Stockton, J.M., Birdsall, N.J., Burgen, A.S., Hulme, E.C. (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol., 23, 551-557.
85. Tache, Y. (2004) Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology? Gut, 53, 919-921.
86. Tibaduiza, E.C., Chen, C., Beinborn, M. (2001) A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J. Biol. Chem., 276, 37787-37793.
87. Tregear, G.W., Van Rietschoten, J., Greene, E., Keutmann, H.T., Niall, H.D., Reit, B., Parsons, J.A., Potts, J.T., Jr. (1973) Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology, 93, 1349-1353.
88. Usdin, T.B., Dobolyi, A., Ueda, H., Palkovits, M. (2003) Emerging functions for tuberoinfundibular peptide of 39 residues. Tends Endocrinol. Metab., 14, 14-19.
89. Webster, E.L., Lewis, D.B., Torpy, D.J., Zachman, E.K., Rice, K.C., Chrousos, G.P. (1996) In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology, 137, 5747-5750.
90. Wysolmerski, J.J., Stewart, A.F. (1998) The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. Annu. Rev. Physiol., 60, 431-460.
91. Zhang, G., Huang, N., Li, Y.W., Qi, X., Marshall, A.P., Yan, X.X., Hill, G., Rominger, C., Prakash, S.R., Bakthavatchalam, R., Rominger, D.H., Gilligan, P.J., Zaczek, R. (2003) Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/ -)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H] SN003) for corticotropin-releasmg factor1 receptors. J. Pharmacol. Exp. Ther., 305, 57-69.
92. Zobel, A.W., Nickel, T., Kunzel, H.E., Ackl, N., Sonntag, A., Ising, M., Holsboer, F. (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res., 34, 171-181.